Who
Randall Michael Giuffre
Director
Company insider
Files Form 4 as: Director, DiaMedica Therapeutics.
In numbers
- Trades disclosed
- 33
- Buys
- 11
- Sells
- 0
- Bought
- $560K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 11 Dec 2018
- Last trade
- 1 Jun 2026
- Last filed
- 3 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Jun 2026filed 3 Jun 2026 | DMAC DiaMedica Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,412 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | DMAC DiaMedica Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,412 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | DMAC DiaMedica TherapeuticsBiotechnology | SEC FORM 4 Code A | $52K6,175 at $8.42 | filing |
| 2 Jan 2026filed 6 Jan 2026 | DMAC DiaMedica TherapeuticsBiotechnology | SEC FORM 4 Code A | $52K6,175 at $8.42 | filing |
| 1 Jun 2025filed 3 Jun 2025 | DMAC DiaMedica Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,162 at $0.00 | filing |
| 13 Feb 2025filed 18 Feb 2025 | DMAC DiaMedica Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —12,000 at $0.00 | filing |
| 13 Feb 2025filed 18 Feb 2025 | DMAC DiaMedica Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,000 at $0.00 | filing |
| 13 Feb 2025filed 18 Feb 2025 | DMAC DiaMedica TherapeuticsBiotechnology | SEC FORM 4 Code M | $25K12,000 at $2.11 | filing |
| 13 Feb 2025filed 18 Feb 2025 | DMAC DiaMedica TherapeuticsBiotechnology | SEC FORM 4 Code M | $18K5,000 at $3.65 | filing |
| 2 Jan 2025filed 3 Jan 2025 | DMAC DiaMedica TherapeuticsBiotechnology | SEC FORM 4 Code A | $58K10,861 at $5.34 | filing |
| 1 Jun 2024filed 3 Jun 2024 | DMAC DiaMedica Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —28,472 at $0.00 | filing |
| 2 Jan 2024filed 2 Jan 2024 | DMAC DiaMedica TherapeuticsBiotechnology | SEC FORM 4 Code A | $54K19,196 at $2.80 | filing |
| 23 Jun 2023filed 26 Jun 2023 | DMAC DiaMedica TherapeuticsBiotechnology | SEC FORM 4 Bought | $254K65,000 at $3.91 | filing |
| 23 Jun 2023filed 26 Jun 2023 | DMAC DiaMedica TherapeuticsBiotechnology | SEC FORM 4 Code G | —15,000 at $0.00 | filing |
| 1 Jun 2023filed 2 Jun 2023 | DMAC DiaMedica Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,968 at $0.00 | filing |
| 3 Jan 2023filed 3 Jan 2023 | DMAC DiaMedica TherapeuticsBiotechnology | SEC FORM 4 Code A | $54K35,130 at $1.53 | filing |
| 9 Dec 2022filed 12 Dec 2022 | DMAC DiaMedica TherapeuticsBiotechnology | SEC FORM 4 Bought | $53K37,079 at $1.43 | filing |
| 8 Dec 2022filed 12 Dec 2022 | DMAC DiaMedica TherapeuticsBiotechnology | SEC FORM 4 Bought | $28K20,000 at $1.40 | filing |
| 7 Dec 2022filed 8 Dec 2022 | DMAC DiaMedica TherapeuticsBiotechnology | SEC FORM 4 Bought | $32K22,574 at $1.40 | filing |
| 6 Dec 2022filed 8 Dec 2022 | DMAC DiaMedica TherapeuticsBiotechnology | SEC FORM 4 Bought | $3,1052,300 at $1.35 | filing |
News
No headline names them, or the companies they trade most, lately.